Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H J Long

Showing results (21-30 of 75) with videos related to

Pageof 8
Sort By:
American Journal of Clinical Oncology|June 1, 1990
Phase II assessment of recombinant leukocyte A interferon with difluoromethylornithine in disseminated malignant melanomaE T Creagan, H J Long, D L Ahmann, et al.
American Journal of Clinical Oncology|October 1, 1984
Phase II evaluation of L-alanosine (NSC-153353) for patients with disseminated malignant melanomaE T Creagan, H J Long, D L Ahmann, et al.
European Journal of Cancer & Clinical Oncology|January 1, 1984
Dose-response relationships of chronic adriamycin toxicity in rabbitsH J Long, S S Diamond, C P Raflo, et al.
American Journal of Clinical Oncology|February 1, 1987
Lack of value for cisplatin added to mitomycin-doxorubicin combination chemotherapy for carcinoma of unknown primary site. A randomized trialR T Eagan, T M Therneau, J Rubin, et al.
Cancer Treatment Reports|July 1, 1987
Phase II study of recombinant alfa-2a interferon in patients with advanced bone sarcomasJ H Edmonson, H J Long, S Frytak, et al.
Cancer|December 15, 1986
Recombinant leukocyte A interferon (rIFN-alpha A) in the treatment of disseminated malignant melanoma. Analysis of complete and long-term responding patientsE T Creagan, D L Ahmann, S Frytak, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 1, 1997
Can molgramostim enhance the antitumor effects of cytotoxic drugs in patients with advanced sarcomas?J H Edmonson, H J Long, L K Kvols, et al.
Cancer Treatment Reports|January 1, 1985
Phase II trial of diaziquone in advanced upper aerodigestive cancerE T Creagan, H J Long, L K Kvols, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 9, 2010
From randomized trial to practice: single institution experience using the GOG 172 i.p. chemotherapy regimen for ovarian cancerG D Aletti, D Nordquist, L Hartmann, et al.
Journal of the National Cancer Institute|June 7, 1989
Phase II study of ifosfamide-etoposide-mesna in adults with advanced nonosseous sarcomasJ H Edmonson, J C Buckner, H J Long, et al.
Pageof 8

Showing results (21-30 of 75) with videos related to

Sort By:
Pageof 8
American Journal of Clinical Oncology|June 1, 1990
Phase II assessment of recombinant leukocyte A interferon with difluoromethylornithine in disseminated malignant melanomaE T Creagan, H J Long, D L Ahmann, et al.
American Journal of Clinical Oncology|October 1, 1984
Phase II evaluation of L-alanosine (NSC-153353) for patients with disseminated malignant melanomaE T Creagan, H J Long, D L Ahmann, et al.
European Journal of Cancer & Clinical Oncology|January 1, 1984
Dose-response relationships of chronic adriamycin toxicity in rabbitsH J Long, S S Diamond, C P Raflo, et al.
American Journal of Clinical Oncology|February 1, 1987
Lack of value for cisplatin added to mitomycin-doxorubicin combination chemotherapy for carcinoma of unknown primary site. A randomized trialR T Eagan, T M Therneau, J Rubin, et al.
Cancer Treatment Reports|July 1, 1987
Phase II study of recombinant alfa-2a interferon in patients with advanced bone sarcomasJ H Edmonson, H J Long, S Frytak, et al.
Cancer|December 15, 1986
Recombinant leukocyte A interferon (rIFN-alpha A) in the treatment of disseminated malignant melanoma. Analysis of complete and long-term responding patientsE T Creagan, D L Ahmann, S Frytak, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 1, 1997
Can molgramostim enhance the antitumor effects of cytotoxic drugs in patients with advanced sarcomas?J H Edmonson, H J Long, L K Kvols, et al.
Cancer Treatment Reports|January 1, 1985
Phase II trial of diaziquone in advanced upper aerodigestive cancerE T Creagan, H J Long, L K Kvols, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 9, 2010
From randomized trial to practice: single institution experience using the GOG 172 i.p. chemotherapy regimen for ovarian cancerG D Aletti, D Nordquist, L Hartmann, et al.
Journal of the National Cancer Institute|June 7, 1989
Phase II study of ifosfamide-etoposide-mesna in adults with advanced nonosseous sarcomasJ H Edmonson, J C Buckner, H J Long, et al.
Pageof 8